Surgical Sealants: Is there a Cohesive Strategy?
This article was originally published in Start Up
Surgical sealants have promise, but can a host of companies convince surgeons that these adjunctive therapies are "need to have" not "nice to have" technologies?
You may also be interested in...
In Vivo interviews device entrepreneur Amar Sawhney whose engineering background led him to Focal Inc. There Sawhney advanced important developments in sealant technology that eventually formed the basis of Confluent Surgical, the first company launched by Incept, Sawhney and fellow entrepreneur's Fred Khosravi's device incubator.
The lead product from Cohera Medical platform technology is a sprayable adhesive strong enough to hold tissue layers together following surgery. TissuGlu is an absorbable, urethane adhesive that is non-toxic for use inside the body. The initial indication will be plastic surgery, with an emphasis on abdominoplasty (tummy tuck). For such a procedure, the product is sprayed in between two flaps of tissue for reattachment, thus preventing fluid buildup that would otherwise occur between unattached layers of tissue and require cumbersome post-surgical drains with their associated complications.
It appears that the climate is becoming more favorable for surgical sealants and adhesives in Europe, according to "European Markets for New and Emerging Wound Closure Products and Techniques" a report published in April 2007 by Medtech Insight, because health care payers want to bridge the gap between an aging population's high-technological medical product requirements and regional health care cost containment initiatives.